Lowest-Rated StocksLowest-RatedNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $1.57 -0.02 (-1.26%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 07/25/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Pliant Therapeutics Stock (NASDAQ:PLRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pliant Therapeutics alerts:Sign Up Key Stats Today's Range$1.55▼$1.6050-Day Range$1.16▼$1.6652-Week Range$1.10▼$16.10Volume560,458 shsAverage Volume1.84 million shsMarket Capitalization$96.38 millionP/E RatioN/ADividend YieldN/APrice Target$13.31Consensus RatingHold Company Overview Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. Read More Pliant Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScorePLRX MarketRank™: Pliant Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 134th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingPliant Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 12 hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has received no research coverage in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.64) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pliant Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pliant Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.83% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 18.75%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.73 Percentage of Shares Shorted4.83% of the float of Pliant Therapeutics has been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 18.75%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.94 News SentimentPliant Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pliant Therapeutics this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24 at 8:39 AM | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.July 26 at 2:00 AM | Weiss Ratings (Ad)Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comSee More Headlines PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $13.17 at the start of the year. Since then, PLRX stock has decreased by 88.1% and is now trading at $1.57. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) released its quarterly earnings data on Monday, March, 3rd. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' top institutional shareholders include HighMark Wealth Management LLC (0.23%) and Vanguard Personalized Indexing Management LLC (0.06%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings3/03/2025Today7/25/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Pliant Therapeutics$13.31 High Price Target$45.00 Low Price Target$1.50 Potential Upside/Downside+747.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$210.30 million Net MarginsN/A Pretax MarginN/A Return on Equity-67.56% Return on Assets-52.54% Debt Debt-to-Equity RatioN/A Current Ratio11.03 Quick Ratio11.03 Sales & Book Value Annual Sales$1.58 million Price / Sales61.00 Cash FlowN/A Price / Cash FlowN/A Book Value$5.00 per share Price / Book0.31Miscellaneous Outstanding Shares61,390,000Free Float56,475,000Market Cap$96.38 million OptionableOptionable Beta1.30 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PLRX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.